Business Description
Anebulo Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US0345691036
Total Employee Number:
3Description
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.84 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 6.4 | |||||
3-Year EPS without NRI Growth Rate | 4.8 | |||||
3-Year FCF Growth Rate | 6.9 | |||||
3-Year Book Growth Rate | -23.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -21.85 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.25 | |||||
9-Day RSI | 51.8 | |||||
14-Day RSI | 49.11 | |||||
3-1 Month Momentum % | -10.23 | |||||
6-1 Month Momentum % | -62.38 | |||||
12-1 Month Momentum % | -85.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.24 | |||||
Quick Ratio | 6.24 | |||||
Cash Ratio | 6.08 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -69.07 | |||||
ROA % | -64.22 | |||||
ROIC % | -3543.31 | |||||
3-Year ROIIC % | 456.12 | |||||
ROCE % | -66.5 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.74 | |||||
Price-to-Tangible-Book | 1.74 | |||||
EV-to-EBIT | -0.58 | |||||
EV-to-EBITDA | -0.58 | |||||
EV-to-FCF | -0.76 | |||||
| Price-to-Net-Current-Asset-Value | 1.74 | |||||
| Price-to-Net-Cash | 1.83 | |||||
Earnings Yield (Greenblatt) % | -172.41 | |||||
FCF Yield % | -43.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ANEB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Anebulo Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.19 | ||
| Beta | -2.975 | ||
| 3-Year Sharpe Ratio | 0.1 | ||
| 3-Year Sortino Ratio | 0.19 | ||
| Volatility % | 213.89 | ||
| 14-Day RSI | 49.11 | ||
| 14-Day ATR ($) | 0.038073 | ||
| 20-Day SMA ($) | 0.31156 | ||
| 12-1 Month Momentum % | -85.21 | ||
| 52-Week Range ($) | 0.0004 - 2.92 | ||
| Shares Outstanding (Mil) | 40.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Anebulo Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Anebulo Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| First quarter earnings results for 2027 | 2026-11-13 | In 104 days | ||
| Annual report for 2026 | 2026-09-29 | In 59 days | ||
| Fourth quarter earnings results for 2026 | 2026-09-29 | In 59 days | ||
| Third quarter earnings results for 2026 | 2026-08-05 16:05 | In 5 days | ||
| General meeting for 2025 | 2026-07-30 | 0.33 (+0.00%) | ||
| Third quarter earnings results for 2026 | 2026-05-13 16:05 | 0.52 (+0.00%) | ||
| General meeting for 2025 | 2026-04-10 09:00 | 0.58 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-02-12 | 0.47 (+0.96%) | ||
| First quarter earnings results for 2026 | 2025-11-13 | 2.37 (+1.33%) | ||
| Annual report for 2025 | 2025-09-29 | 2.40 (-1.23%) |
Show
Entries
Anebulo Pharmaceuticals Inc Frequently Asked Questions
What is Anebulo Pharmaceuticals Inc(ANEB)'s stock price today?
The current price of ANEB is $0.33. The 52 week high of ANEB is $2.92 and 52 week low is $0.00.
When is next earnings date of Anebulo Pharmaceuticals Inc(ANEB)?
The next earnings date of Anebulo Pharmaceuticals Inc(ANEB) is 2026-08-05 Est..
Does Anebulo Pharmaceuticals Inc(ANEB) pay dividends? If so, how much?
Anebulo Pharmaceuticals Inc(ANEB) does not pay dividend.
Guru Commentaries on OTCPK:ANEB
No articles.
Press Release
Articles on Anebulo Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers